GVBL.BO · BSE
GENOMIC VALLEY BIOTECH LIMITED
₹28.73
-4.99% (-₹1.51)
Prev. close
₹30.24
Volume
723
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About GENOMIC VALLEY BIOTECH LIMITED
Genomic Valley Biotech Limited operates in horticulture business activities in India. The company involved in the commercial greenhouse/poly house cultivation of crops; commercial horticulture activities with aloe vera, tomato, bitter gourd, bottle gourd, brinjal, broccoli, cabbage, capsicum, carrot, cauliflower, cucumber, green chilies, onion, radish, ridge/sponge gourd, leafy vegetables, pumpkin, banana, guava, papaya, and strawberry; and commercial floriculture of flowers. It also undertakes contracts for its clients for erecting greenhouses; and provides turnkey consultancy services. In addition, the company manufactures and markets bio-fertilizers; and offers farmer support apps. Further, it is involved in the operation of plant tissue culture process laboratory to produce tissue cultured plantlets. The company was incorporated in 1994 and is based in Delhi, India.
Details
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Yogesh Agrawal
Headquarters
Delhi
Website
genomicvalley.comExchange
View on BSE ↗Key stats
Market cap
₹8.78 Cr
P/E ratio (TTM)
410.4
EPS (TTM)
₹0.07
Beta (1Y · daily vs NIFTY 50)
0.43
Beta (5Y · monthly vs NIFTY 50)
0.37
Shares float
7.16 L
EPS · quarter ended Jun 2026
₹0.05
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide. EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹20.80 L | ₹7.10 L | ₹2.72 Cr | ₹16.51 L | ₹84.39 L | ₹26.75 L | |
| EBITDA | — | — | ₹65.70 L | ₹1.67 L | ₹44.40 L | ₹4.37 L |
| ₹-55.90 L | ₹-90,000 | ₹64.83 L | ₹1.52 L | ₹35.61 L | ₹3.03 L | |
| Diluted EPS | ₹-1.83 | ₹-0.03 | ₹2.12 | ₹0.05 | ₹1.17 | ₹0.1 |
Depreciation & amortisation, EBITDA, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹4.42 Cr | ₹4.33 Cr | ₹4.36 Cr | ₹4.25 Cr | |
| — | — | ₹0 | ₹0 | ₹0 | ₹0 | |
| Stockholders' equity | — | — | ₹3.53 Cr | ₹3.54 Cr | ₹3.90 Cr | ₹3.93 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated. Inventory shows ₹0 for 2023-03-31, 2024-03-31 — this deck's own annual-report reading has no Inventory figure for this filer in any year shown (2023-03-31, 2024-03-31, 2021-03-31, 2022-03-31 alike); the ₹0 shown here comes from this filer's own reported data feed rather than this deck's own extraction, and is positively consistent with a filer that holds no physical inventory (typical for lenders and other financial-services companies) rather than a display default. 2021-03-31, 2022-03-31 have no Inventory figure reaching this deck at all — not shown as zero, not shown as positive — left blank rather than assumed to match the other years.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹-77.87 L | ₹-2.01 L | ₹2.69 L | ₹-1.90 L | |
| Investing cash flow | — | — | ₹1.52 Cr | ₹-1.52 L | ₹1.20 L | ₹0 |
| — | — | ₹-70.45 L | ₹0 | ₹0 | ₹0 | |
| Capital expenditure | — | — | — | — | ₹-91,763 | — |
| End cash position | — | — | ₹4.13 L | ₹60,734 | ₹4.52 L | ₹2.62 L |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| GENOMIC VALLEY BIOTECH LIMITED | ₹9.24 Cr | ₹30.24 | 432.0 | 2.35 | 0.8% | 0.00 | -68.3% | -18.9% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 14
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.